Litwin V, Gumperz J, Parham P, Phillips J H, Lanier L L
Department of Human Immunology, DNAX Research Institute of Molecular and Cellular Biology, Inc., Palo Alto, California 94304.
J Exp Med. 1994 Aug 1;180(2):537-43. doi: 10.1084/jem.180.2.537.
Natural killer (NK) cells kill normal and transformed hematopoietic cells that lack expression of major histocompatibility complex (MHC) class I antigens. Lysis of HLA-negative Epstein Barr virus-transformed B lymphoblastoid cell lines (B-LCL) by human NK cell clones can be inhibited by transfection of the target cells with certain HLA-A, -B, or -C alleles. NK cell clones established from an individual demonstrate clonal heterogeneity in HLA recognition and a single NK clone can recognize multiple alleles. We describe a potential human NK cell receptor (NKB1) for certain HLA-B alleles (e.g., HLA-B5101 and-B5801) identified by the mAb DX9. NKB1 is a 70-kD glycoprotein that is expressed on a subset of NK cells and NK cell clones. DX9 monoclonal antibody (mAb) specifically inhibits the interaction between NK cell clones and B-LCL targets transfected with certain HLA-B alleles, but does not affect recognition of HLA-A or HLA-C antigens. An individual NK cell clone can independently recognize B-LCL targets transfected with HLA-B or HLA-C antigens; however, DX9 mAb only affects interaction with transfectants expressing certain HLA-B alleles. These findings demonstrate the existence of NK cell receptors involved in the recognition of HLA-B and imply the presence of multiple receptors for MHC on an individual NK clone.
自然杀伤(NK)细胞可杀伤缺乏主要组织相容性复合体(MHC)I类抗原表达的正常和转化造血细胞。人NK细胞克隆对HLA阴性的爱泼斯坦-巴尔病毒转化的B淋巴母细胞系(B-LCL)的裂解作用,可通过用某些HLA-A、-B或-C等位基因转染靶细胞而受到抑制。从个体建立的NK细胞克隆在HLA识别方面表现出克隆异质性,单个NK克隆可识别多个等位基因。我们描述了一种由单克隆抗体DX9鉴定的针对某些HLA-B等位基因(如HLA-B5101和-B5801)的潜在人类NK细胞受体(NKB1)。NKB1是一种70-kD糖蛋白,在一部分NK细胞和NK细胞克隆上表达。DX9单克隆抗体(mAb)可特异性抑制NK细胞克隆与用某些HLA-B等位基因转染的B-LCL靶细胞之间的相互作用,但不影响对HLA-A或HLA-C抗原的识别。单个NK细胞克隆可独立识别用HLA-B或HLA-C抗原转染的B-LCL靶细胞;然而,DX9 mAb仅影响与表达某些HLA-B等位基因的转染细胞的相互作用。这些发现证明了参与HLA-B识别的NK细胞受体的存在,并暗示单个NK克隆上存在多种MHC受体。